bluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Shares of Stock

bluebird bio, Inc. (NASDAQ:BLUE) insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.54, for a total transaction of $388,215.00. Following the transaction, the insider now owns 28,734 shares of the company’s stock, valued at approximately $4,957,764.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

bluebird bio, Inc. (NASDAQ:BLUE) traded up $0.35 during mid-day trading on Wednesday, reaching $162.65. 563,600 shares of the company traded hands, compared to its average volume of 825,312. bluebird bio, Inc. has a 52 week low of $60.95 and a 52 week high of $174.65.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s quarterly revenue was up 397.4% on a year-over-year basis. During the same period in the prior year, the business earned ($2.07) EPS. analysts forecast that bluebird bio, Inc. will post -6.68 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on BLUE. BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Morgan Stanley restated a “hold” rating on shares of bluebird bio in a research report on Wednesday, August 9th. Leerink Swann restated an “outperform” rating and set a $120.00 target price on shares of bluebird bio in a research report on Saturday, September 30th. Canaccord Genuity began coverage on shares of bluebird bio in a research report on Tuesday. They set a “buy” rating and a $202.00 target price for the company. Finally, Jefferies Group restated a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $137.57.

A number of hedge funds have recently bought and sold shares of BLUE. Dimensional Fund Advisors LP increased its stake in bluebird bio by 24.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 84,961 shares of the biotechnology company’s stock worth $7,723,000 after buying an additional 16,741 shares during the period. Bank of Montreal Can increased its position in bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the period. Aperio Group LLC increased its position in bluebird bio by 10.9% during the 2nd quarter. Aperio Group LLC now owns 5,001 shares of the biotechnology company’s stock valued at $525,000 after purchasing an additional 491 shares during the period. Russell Investments Group Ltd. increased its position in bluebird bio by 15.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 38,882 shares of the biotechnology company’s stock valued at $4,084,000 after purchasing an additional 5,059 shares during the period. Finally, Strs Ohio increased its position in bluebird bio by 25.4% during the 2nd quarter. Strs Ohio now owns 7,400 shares of the biotechnology company’s stock valued at $777,000 after purchasing an additional 1,500 shares during the period.

WARNING: “bluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Shares of Stock” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://stocknewstimes.com/2017/12/06/bluebird-bio-inc-blue-insider-philip-d-gregory-sells-2250-shares-of-stock.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply